Valuation: Insulet Corporation

Market Cap 11.55B 10B 9.33B 8.58B 16.19B 1,099B 16.38B 110B 43B 550B 43.39B 42.44B 1,822B P/E 2026 *
26.4x
P/E 2027 * 20.9x
Enterprise Value 11.62B 10.06B 9.38B 8.64B 16.29B 1,106B 16.48B 110B 43.26B 553B 43.66B 42.69B 1,833B EV / Sales 2026 *
3.5x
EV / Sales 2027 * 2.86x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day-20.12%
1 week-20.43%
Current month-19.41%
1 month-18.98%
3 months-22.25%
6 months-46.96%
Current year-53.12%
1 week 126.4
Extreme 126.4
172.1
1 month 126.4
Extreme 126.4
172.92
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 2025-04-27
Director of Finance/CFO 53 2025-09-29
Compliance Officer 50 2022-11-30
Director TitleAgeSince
Chairman 61 2018-12-31
Director/Board Member 61 2015-07-26
Director/Board Member 59 2017-08-09
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Free

Director

1,355 0.0019%
7/1/26 Other

Director

0 0%
6/30/26 Free

Director

151 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-20.12%-20.43%-53.69%-49.36% 11.55B
+0.24%-1.45%-18.64%-1.80% 182B
-0.24%-1.02%-4.07%+2.32% 110B
+3.57%-0.74%+8.03%+71.16% 59.59B
-0.10%+9.35%+43.37%+59.19% 55.04B
+0.32%+2.60%-4.61%-36.98% 46.87B
-12.79%-9.49% - - 35.55B
-4.92%+10.43%+8.41%-31.31% 32.81B
+0.65%+4.16%+47.25%-6.41% 24.54B
-0.06%+1.03%+1.87%+2.96% 22.69B
Average -3.34%+3.47%+3.10%+1.09% 58.15B
Weighted average by Cap. -1.02%+1.51%-0.63%+7.34%

Financials

2026 *2027 *
Net sales 3.32B 2.87B 2.68B 2.47B 4.65B 316B 4.71B 31.47B 12.35B 158B 12.47B 12.19B 523B 3.92B 3.4B 3.17B 2.91B 5.5B 373B 5.56B 37.19B 14.6B 187B 14.73B 14.41B 619B
Net income 427M 369M 344M 317M 598M 40.57B 605M 4.04B 1.59B 20.29B 1.6B 1.57B 67.27B 565M 489M 456M 420M 792M 53.74B 801M 5.36B 2.1B 26.88B 2.12B 2.08B 89.11B
Net Debt 69.76M 60.39M 56.31M 51.82M 97.73M 6.63B 98.92M 661M 260M 3.32B 262M 256M 11B -340M -294M -274M -253M -476M -32.34B -482M -3.22B -1.27B -16.17B -1.28B -1.25B -53.61B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
26-08-05 US$133.26 -20.12% 7,143,932
26-08-04 US$166.82 -1.70% 1,749,128
26-08-03 US$169.70 +2.63% 1,408,011
26-07-31 US$165.35 -0.20% 1,314,052
26-07-30 US$165.68 -2.90% 1,215,698
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
166.82USD
Average target price
233.46USD
Spread / Average Target
+39.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock